Semaglutide

Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.

Gastric inhibitory polypeptide (GIP)/Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a...

🗓️ 2026-01-24
📰 Publication: British Journal Of Pharmacology
Read MoreGlucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!